Alto Neuroscience (NYSE:ANRO) Stock Price Down 6.9% – Here’s Why

Alto Neuroscience, Inc. (NYSE:ANRO) fell 6.9% on Wednesday . The stock traded as low as $19.78 and last traded at $19.6890. 101,812 shares traded hands during trading, a decline of 64% from the average session volume of 286,108 shares. The stock had previously closed at $21.15.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ANRO. Chardan Capital reiterated a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Wedbush upped their price objective on shares of Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. JonesTrading dropped their price objective on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Weiss Ratings upgraded shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Alto Neuroscience in a report on Wednesday, May 27th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Stock Up 8.5%

The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. The company has a market cap of $749.52 million, a price-to-earnings ratio of -8.83 and a beta of 1.22. The stock’s fifty day moving average is $22.75 and its two-hundred day moving average is $19.49.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). Sell-side analysts predict that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently made changes to their positions in ANRO. Commodore Capital LP acquired a new stake in shares of Alto Neuroscience in the 4th quarter worth about $32,453,000. Perceptive Advisors LLC raised its holdings in shares of Alto Neuroscience by 1,048.5% in the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after acquiring an additional 1,629,027 shares during the last quarter. Vestal Point Capital LP raised its holdings in shares of Alto Neuroscience by 161.6% in the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after acquiring an additional 1,535,000 shares during the last quarter. Spruce Street Capital LP raised its holdings in shares of Alto Neuroscience by 494.7% in the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock worth $29,116,000 after acquiring an additional 1,102,366 shares during the last quarter. Finally, Vivo Capital LLC acquired a new stake in shares of Alto Neuroscience in the 4th quarter worth about $18,433,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.